Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT02598193 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

89

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG: Nintedanib
DRUG: Pirfenidone

Sponsor

Hoffmann-La Roche